Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Treasury Shares (2022 - 2025)

Ocular Therapeutix has reported Treasury Shares over the past 5 years, most recently at $4.4 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 28.61% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, up 28.61%, while the annual FY2025 figure was $4.4 million, 28.61% up from the prior year.
  • Treasury Shares for Q4 2025 was $4.4 million at Ocular Therapeutix, up from $3.4 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $4.4 million in Q4 2025 and troughed at $1.1 million in Q4 2022.
  • A 4-year average of $2.6 million and a median of $2.5 million in 2023 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: surged 108.29% in 2024 and later grew 28.61% in 2025.
  • Year by year, Treasury Shares stood at $1.1 million in 2022, then surged by 48.93% to $1.6 million in 2023, then surged by 108.29% to $3.4 million in 2024, then grew by 28.61% to $4.4 million in 2025.
  • Business Quant data shows Treasury Shares for OCUL at $4.4 million in Q4 2025, $3.4 million in Q4 2024, and $1.6 million in Q4 2023.